Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice
Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, ag...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
CHUNG, BYUNG HA [verfasserIn] HONG, SUNG JOON [verfasserIn] LEE, MOO SANG [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Melbourne, Australia: Blackwell Science Pty ; 2005 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2005 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: International journal of urology - Oxford [u.a.] : Wiley-Blackwell, 1997, 12(2005), 2, Seite 0 |
| Übergeordnetes Werk: |
volume:12 ; year:2005 ; number:2 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1442-2042.2005.00998.x |
|---|
| Katalog-ID: |
NLEJ242678327 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242678327 | ||
| 003 | DE-627 | ||
| 005 | 20230505205721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1442-2042.2005.00998.x |2 doi | |
| 035 | |a (DE-627)NLEJ242678327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a CHUNG, BYUNG HA |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice |
| 264 | 1 | |a Melbourne, Australia |b Blackwell Science Pty |c 2005 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. | ||
| 533 | |d 2005 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2005|||||||||| | ||
| 650 | 4 | |a drug therapy | |
| 700 | 1 | |a HONG, SUNG JOON |e verfasserin |4 aut | |
| 700 | 1 | |a LEE, MOO SANG |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International journal of urology |d Oxford [u.a.] : Wiley-Blackwell, 1997 |g 12(2005), 2, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243925654 |w (DE-600)2009793-1 |x 1442-2042 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2005 |g number:2 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2005 |e 2 |h 0 | ||
| author_variant |
b h c bh bhc s j h sj sjh m s l ms msl |
|---|---|
| matchkey_str |
article:14422042:2005----::oaoifreinrsaihprlsanpnaebslncnrles |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1111/j.1442-2042.2005.00998.x doi (DE-627)NLEJ242678327 DE-627 ger DE-627 rakwb CHUNG, BYUNG HA verfasserin aut Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice Melbourne, Australia Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| drug therapy HONG, SUNG JOON verfasserin aut LEE, MOO SANG verfasserin aut In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 12(2005), 2, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:12 year:2005 number:2 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 12 2005 2 0 |
| spelling |
10.1111/j.1442-2042.2005.00998.x doi (DE-627)NLEJ242678327 DE-627 ger DE-627 rakwb CHUNG, BYUNG HA verfasserin aut Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice Melbourne, Australia Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| drug therapy HONG, SUNG JOON verfasserin aut LEE, MOO SANG verfasserin aut In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 12(2005), 2, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:12 year:2005 number:2 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 12 2005 2 0 |
| allfields_unstemmed |
10.1111/j.1442-2042.2005.00998.x doi (DE-627)NLEJ242678327 DE-627 ger DE-627 rakwb CHUNG, BYUNG HA verfasserin aut Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice Melbourne, Australia Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| drug therapy HONG, SUNG JOON verfasserin aut LEE, MOO SANG verfasserin aut In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 12(2005), 2, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:12 year:2005 number:2 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 12 2005 2 0 |
| allfieldsGer |
10.1111/j.1442-2042.2005.00998.x doi (DE-627)NLEJ242678327 DE-627 ger DE-627 rakwb CHUNG, BYUNG HA verfasserin aut Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice Melbourne, Australia Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| drug therapy HONG, SUNG JOON verfasserin aut LEE, MOO SANG verfasserin aut In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 12(2005), 2, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:12 year:2005 number:2 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 12 2005 2 0 |
| allfieldsSound |
10.1111/j.1442-2042.2005.00998.x doi (DE-627)NLEJ242678327 DE-627 ger DE-627 rakwb CHUNG, BYUNG HA verfasserin aut Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice Melbourne, Australia Blackwell Science Pty 2005 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. 2005 Blackwell Publishing Journal Backfiles 1879-2005 |2005|||||||||| drug therapy HONG, SUNG JOON verfasserin aut LEE, MOO SANG verfasserin aut In International journal of urology Oxford [u.a.] : Wiley-Blackwell, 1997 12(2005), 2, Seite 0 Online-Ressource (DE-627)NLEJ243925654 (DE-600)2009793-1 1442-2042 nnns volume:12 year:2005 number:2 pages:0 http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 12 2005 2 0 |
| source |
In International journal of urology 12(2005), 2, Seite 0 volume:12 year:2005 number:2 pages:0 |
| sourceStr |
In International journal of urology 12(2005), 2, Seite 0 volume:12 year:2005 number:2 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
drug therapy |
| isfreeaccess_bool |
false |
| container_title |
International journal of urology |
| authorswithroles_txt_mv |
CHUNG, BYUNG HA @@aut@@ HONG, SUNG JOON @@aut@@ LEE, MOO SANG @@aut@@ |
| publishDateDaySort_date |
2005-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243925654 |
| id |
NLEJ242678327 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242678327</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505205721.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1442-2042.2005.00998.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242678327</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">CHUNG, BYUNG HA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Melbourne, Australia</subfield><subfield code="b">Blackwell Science Pty</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug therapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">HONG, SUNG JOON</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">LEE, MOO SANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of urology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1997</subfield><subfield code="g">12(2005), 2, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925654</subfield><subfield code="w">(DE-600)2009793-1</subfield><subfield code="x">1442-2042</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
CHUNG, BYUNG HA |
| spellingShingle |
CHUNG, BYUNG HA misc drug therapy Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice |
| authorStr |
CHUNG, BYUNG HA |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243925654 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Melbourne, Australia |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1442-2042 |
| topic_title |
Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice drug therapy |
| publisher |
Blackwell Science Pty |
| publisherStr |
Blackwell Science Pty |
| topic |
misc drug therapy |
| topic_unstemmed |
misc drug therapy |
| topic_browse |
misc drug therapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
International journal of urology |
| hierarchy_parent_id |
NLEJ243925654 |
| hierarchy_top_title |
International journal of urology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243925654 (DE-600)2009793-1 |
| title |
Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice |
| ctrlnum |
(DE-627)NLEJ242678327 |
| title_full |
Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice |
| author_sort |
CHUNG, BYUNG HA |
| journal |
International journal of urology |
| journalStr |
International journal of urology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
CHUNG, BYUNG HA HONG, SUNG JOON LEE, MOO SANG |
| container_volume |
12 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
CHUNG, BYUNG HA |
| doi_str_mv |
10.1111/j.1442-2042.2005.00998.x |
| author2-role |
verfasserin |
| title_sort |
doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in korean general practice |
| title_auth |
Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice |
| abstract |
Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. |
| abstractGer |
Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. |
| abstract_unstemmed |
Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
2 |
| title_short |
Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice |
| url |
http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x |
| remote_bool |
true |
| author2 |
HONG, SUNG JOON LEE, MOO SANG |
| author2Str |
HONG, SUNG JOON LEE, MOO SANG |
| ppnlink |
NLEJ243925654 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1111/j.1442-2042.2005.00998.x |
| up_date |
2024-07-06T02:49:28.929Z |
| _version_ |
1803796263919943680 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242678327</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505205721.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1442-2042.2005.00998.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242678327</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">CHUNG, BYUNG HA</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Doxazosin for benign prostatic hyperplasia: An open-label, baseline-controlled study in Korean general practice</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Melbourne, Australia</subfield><subfield code="b">Blackwell Science Pty</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Few studies have reported the treatment of benign prostatic hyperplasia (BPH) in Asian patients. We assessed the safety and efficacy of doxazosin, a selective α1-adrenoceptor antagonist, in the treatment of Korean patients with symptomatic BPH.Methods: Two hundred and ninety-five men, aged 48 years or older with clinical BPH, were enrolled in a 12-week, open-label, baseline-controlled, dose-titration, multicenter study. A 2-week, single-blind, placebo run-in was followed by 10 weeks of doxazosin treatment, initially administered at 1 mg/day, with upward titrations (2, 4, or 8 mg/day) at 2-week intervals. The international prostate symptom score (IPSS) was used to assess efficacy after 4, 6, and 10 weeks of active treatment.Results: The intent-to-treat (ITT) population comprised 249 patients (mean age 63.6 years). Doxazosin significantly reduced the mean total IPSS by 48%; similarly, the obstructive and irritative subscores were reduced from baseline by 51% and 39%, respectively (P < 0.001 for all scores: Wilcoxon rank sum test). In a subset analysis of 170 normotensive and 78 hypertensive patients, significant reductions in mean systolic and diastolic blood pressures relative to baseline were observed only in the hypertensive subset (P < 0.01). Similar results in mean IPSS were observed in older (≥65 years, n = 100) and younger (45–64 years, n = 140) patients, as well as between normotensive and hypertensive patients. Thirty-nine patients reported adverse events: The most frequent were dizziness, dyspepsia, asthenia, somnolence, and dry mouth.Conclusions: The efficacy and safety of doxazosin treatment for BPH were confirmed in this Asian population. Significant improvements in total IPSS, as well as obstructive and irritative subscores, were observed.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2005</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2005||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">drug therapy</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">HONG, SUNG JOON</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">LEE, MOO SANG</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of urology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1997</subfield><subfield code="g">12(2005), 2, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243925654</subfield><subfield code="w">(DE-600)2009793-1</subfield><subfield code="x">1442-2042</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1442-2042.2005.00998.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.399727 |